Status: Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
Participants needed: 345
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Nurix Therapeutics, Inc.Updated: Sep 9, 2025Locations: 17
Eligibility criteria
Age ≥ 18 years. [+10]
Active untreated brain metastases. [+30]